StreetInsider.com News Articles

Rakovina Therapeutics plans $1.5M private placement

Wed, 15 Jul 2026 16:32:50 -0400

Rakovina Therapeutics Inc. (TSX-V: RKV, FSE: 7JO0) announced a non-brokered private placement of up to $1.5 million, according to a press release from the Vancouver-based biopharmaceutical company.

The offering consists of up to 15 million units priced at $0.10 per unit. Each unit includes one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, exercisable for 24 months from issuance.

The company stated that proceeds will primarily fund in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and AI-driven lead optimization through its

Rakovina Therapeutics plans $1.5M private placement

Wed, 15 Jul 2026 16:32:50 -0400

Rakovina Therapeutics Inc. (TSX-V: RKV, FSE: 7JO0) announced a non-brokered private placement of up to $1.5 million, according to a press release from the Vancouver-based biopharmaceutical company.

The company stated that proceeds will primarily fund in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and AI-driven lead optimization through its

Rakovina Therapeutics plans $1.5M private placement

Wed, 15 Jul 2026 16:32:50 -0400

Rakovina Therapeutics Inc. (TSX-V: RKV, FSE: 7JO0) announced a non-brokered private placement of up to $1.5 million, according to a press release from the Vancouver-based biopharmaceutical company.

The company stated that proceeds will primarily fund in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and AI-driven lead optimization through its

Rakovina Therapeutics Announces $1.5 Million Private Placement

Wed, 15 Jul 2026 16:32:00 -0400

VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announces a non-brokered private placement offering (the “Offering”) of up to $1.5 million.

Pursuant to the Offering, Rakovina will issue up to 15 million equity units (“Units”) at an offering price of $0.10 per Unit, with each Unit consisting of one common share and one-half of one common share purchase warrant (a “Warrant”). Each whole Warrant will entitle the holder to acquire one additional common

Rakovina Therapeutics Announces $1.5 Million Private Placement

Wed, 15 Jul 2026 16:32:00 -0400

Rakovina Therapeutics Announces $1.5 Million Private Placement

Wed, 15 Jul 2026 16:32:00 -0400

Rakovina Therapeutics Announces $1.5 Million Private Placement

Wed, 15 Jul 2026 16:32:00 -0400

Rakovina Therapeutics Announces $1.5 Million Private Placement

Wed, 15 Jul 2026 16:32:00 -0400

Rakovina Therapeutics Announces $1.5 Million Private Placement

Wed, 15 Jul 2026 16:32:00 -0400

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended March 31, 2026 (“Q1 2026”), and provided an update on recent corporate developments.